Medibiofarma announced the nomination of a new Development Candidate, the compound MBF-118, a novel PPAR-y receptor antagonist for the treatment of bladder cancer. The compound will start IND enabling studies the second quarter 2018. https://www.palobiofarma.com/palobiofarma-completed-the-dose-escalation-part-of-the-phase-i-study-with-pbf-999-in-cancer-patients/